1. Home
  2. FIVN vs COAG Comparison

FIVN vs COAG Comparison

Compare FIVN & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Five9 Inc.

FIVN

Five9 Inc.

N/A

Current Price

$22.68

Market Cap

2.1B

Sector

Technology

ML Signal

N/A

COAG

Hemab Therapeutics Holdings Inc. Common Stock

N/A

Current Price

$39.38

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FIVN
COAG
Founded
2001
2020
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
FIVN
COAG
Price
$22.68
$39.38
Analyst Decision
Buy
Strong Buy
Analyst Count
21
7
Target Price
$35.50
★ $63.00
AVG Volume (30 Days)
★ 1.8M
452.2K
Earning Date
11-05-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ 0.47
N/A
Revenue
★ $1,149,088,000.00
N/A
Revenue This Year
$10.75
N/A
Revenue Next Year
$9.55
N/A
P/E Ratio
$49.27
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.29
$27.38
52 Week High
$40.00
$55.42

Technical Indicators

Market Signals
Indicator
FIVN
COAG
Relative Strength Index (RSI) 22.65 50.64
Support Level $20.30 $35.00
Resistance Level $26.27 $51.07
Average True Range (ATR) 1.87 3.66
MACD -0.95 -0.44
Stochastic Oscillator 0.78 28.98

Price Performance

Historical Comparison
FIVN
COAG

About FIVN Five9 Inc.

Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud-based contact-center-as-a-service platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: